Radiolabeled 89Zr-DFO-girentuximab PET/CT can accurately and noninvasively identify clear cell renal carcinoma, with minimal toxicity, say researchers reporting results from the phase 3 ZIRCON trial.
A cancer screening program in Arizona that offers the Galleri blood test to first responders provides some insight into how well the test can catch cancers in this high-risk group.
Perhaps one of your patients could benefit from clinical trials that are currently recruiting patients with urologic cancers, including prostate cancer.
Across 23 types of solid cancer, 5-year survival reached between 50% and 100% for 17, and there was even marked improvement for the six most fatal types.
Taking dietary supplements alongside cancer therapies can reduce the effects of treatment. Here s how patients and physicians can communicate about supplements and their potential risks.